Get the Stockscreener App
15.55
0.06%
0.01
Polyrizon Ltd stock is traded at $15.55, with a volume of 49,900.
It is up +0.06% in the last 24 hours and up +38.96% over the past month.
Polyrizon Ltd is a clinical development stage biotech company specializing in the development of nasal gels to provide preventative treatment to protect against a wide cross-section of viruses, including certain variants of COVID-19 that are also considered to cause more infections and spread faster than the original strain of the virus (the CDC expects that additional variants of the virus will continue to occur), influenza, allergens, and other toxins. Its technology platforms are Capture & Contain and Trap & Target.
See More
Previous Close:
$15.54
Open:
$15
24h Volume:
49,900
Relative Volume:
0.02
Market Cap:
$16.20M
Revenue:
-
Net Income/Loss:
$-1.13M
P/E Ratio:
-0.272
EPS:
-57.1626
Net Cash Flow:
$-2.63M
1W Performance:
+21.58%
1M Performance:
+38.96%
6M Performance:
+146.83%
1Y Performance:
-99.29%
1-Day Range:
$14.85
$15.80
1-Week Range:
$11.60
$15.80
52-Week Range:
$2.88
$2,550.00
Polyrizon Ltd Stock (PLRZ) Company Profile
Compare PLRZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLRZ
Polyrizon Ltd
|
15.55 | 16.19M | 0 | -1.13M | -2.63M | -57.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Polyrizon Ltd Stock (PLRZ) Latest News
Polyrizon recives Nasdaq delisting notice - MSN
Polyrizon explores investments in defense, aviation and AI sectors By Investing.com - Investing.com Nigeria
Polyrizon Ltd to explore revenue-generating investment opportunities in high-growth sectors - marketscreener.com
Polyrizon to Explore Revenue-Generating Investment Opportunities in High-Growth Sectors, Leveraging Strong Cash Position and Debt-Free Balance Sheet - The Manila Times
Debt-free biotech Polyrizon hunts revenue in AI, aviation and defense - Stock Titan
Polyrizon (PLRZ) Stock Explodes on Naloxone Hydrogel Breakthrough and PL‑14 Upscaling – What Investors Should Know Now - TechStock²
Polyrizon Ltd. (PLRZ) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Can Polyrizon Ltd. stock rebound after recent weaknessPortfolio Gains Report & Technical Pattern Recognition Alerts - Улправда
PLRZ - Finviz
Is Polyrizon Ltd. stock undervalued vs historical averagesNew Releases Roundup & what to check before ordering - Улправда
Polyrizon names allergy blocker product NASARIX By Investing.com - Investing.com Australia
Why Polyrizon Ltd. stock is favored by top institutions2025 Winners & Losers & Fast Moving Trade Plans - Улправда
Polyrizon expects Nasarix introduction aligned with clinical progress - marketscreener.com
Polyrizon names allergy blocker product NASARIX - Investing.com
Polyrizon Brands PL-14 Intranasal Allergy Blocker as NASARIX™ - TipRanks
Polyrizon Completes Branding Process for PL-14 Allergy Blocker with Brand Name NASARIX™ - The Manila Times
Polyrizon Completes Branding Process for PL-14 Allergy Blocker with Brand Name NASARIX - Bluefield Daily Telegraph
NASARIX: a new nasal spray brand designed to shield against allergens - Stock Titan
Polyrizon’s PL-14 shows strong pre-clinical allergen-blocking advantage over standard nasal barrier - MSN
Polyrizon announces in-vitro results for PL-16 Viral Blocker - MSN
Polyrizon stock rises after positive pre-clinical allergy blocker results By Investing.com - Investing.com Nigeria
Polyrizon stock rises after positive pre-clinical allergy blocker results - Investing.com
Polyrizon Announces Positive Data From PL-14 Allergy Blocker Formulation Study - Nasdaq
Polyrizon’s nasal allergy blocker outperforms standard in lab study By Investing.com - Investing.com South Africa
Polyrizon’s PL-14 Shows Strong Pre-Clinical Allergen-Blocking Advantage Over Standard Nasal Barrier - TipRanks
Polyrizon’s nasal allergy blocker outperforms standard in lab study - Investing.com India
Polyrizon Announces New Pre-Clinical Results: PL-14 Demonstrates Significant Allergen-Blocking Performance Compared to a Standard Comparator - The Manila Times
About Us - FinancialContent
Polyrizon submits pre-request to FDA for nasal spray against flu - Investing.com Nigeria
Polyrizon submits pre-request to FDA for nasal spray against flu By Investing.com - Investing.com South Africa
Polyrizon stock rises on FDA submission for PL-16 viral blocker - Investing.com Australia
As Flu Surge Continues, Polyrizon's Nasal Spray Emerges as Potential Extra Shield Solution for Both Vaccinated and Unvaccinated - The Manila Times
Polyrizon (PLRZ) Stock Analysis Report | Financials & Insights - Benzinga
Polyrizon reports mucoadhesion results for intranasal naloxone hydrogel - MSN
Polyrizon Ltd. to Explore Investment Opportunities in Revenue-Generating Real Assets - marketscreener.com
Polyrizon to explore investments in revenue-generating assets By Investing.com - Investing.com Nigeria
Polyrizon to pursue revenue-generating real assets while advancing intranasal biotech pipeline - MSN
Polyrizon stock rises as company explores revenue-generating investments By Investing.com - Investing.com Nigeria
symbol__ Stock Quote Price and Forecast - CNN
Polyrizon Ltd Stock (PLRZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.73%
0.92%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):